Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6339 | SA 4503 dihydrochloride |
| Selective σ1 receptor agonist (IC50 = 17.4 nM). Exhibits selectivity for σ1 over σ2 receptors. Inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro and attenuates myocardial hypertrophy in vivo. Enhances brain plasticity and sensorimotor function in a rat model of experimental stroke. | |
| BCC6340 | UAMC 00039 dihydrochloride |
| Potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM). Exhibits selectivity for DPP-II against DPP-9, DPP-8 and DPP-IV (IC50 values are 78.6, 142 and 165 μM, respectively). Orally available. | |
| BCC6341 | 4-[4-(3-Hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid |
| Selective GPR55 antagonist. Inhibits LPI-induced Ca2+ signaling (IC50 = 0.21 μM in HEK-GPR55 cells), ERK1/2 phosphorylation and GPR55-mediated transcription factor activation. Displays weak inhibition of acetylcholinesterase, μ-opioid receptor, KCNH2 and hERG. Decreases LPI-induced GPR55 internalization. Reduces experimental intestinal inflammation in mice. | |
| BCC6345 | ML 337 |
| Selective negative allosteric modulator of mGlu3 (IC50 = 593 nM). Displays no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 30 μM. Brain penetrant. | |
| BCC6347 | CK 869 |
| Inhibitor of human and bovine actin-related protein 2/3 (Arp2/3) complex. Inhibits actin polymerization (IC50= 11 μM). Does not inhibit budding or fission yeast Arp2/3 complexes. | |
| BCC6349 | INDY |
| DYRK1A/B inhibitor (IC50 values are 0.23 and 0.24 μM, for DYRK1B and DYRKA respectively). Binds at the ATP-binding cleft of the enzyme. Reverses aberrant tau-phosphorylation and rescues repressed calcineurin/NFAT signaling. Impairs the self-renewal capacity of subventricular zone neural stem cells. Also available as a prodrug, proINDY. | |
| BCC6354 | PRT 4165 |
| Inhibitor of Bmi1/Ring1A, subunits of the polycomb repressive complex 1 (PRC1); inhibits self-ubiquitination (IC50 = 3.9 μM) but does not increase cellular levels of either subunit. Prevents Bmi1/Ring1A-mediated ubiquitination and drug-induced degradation of topoisomerase 2α (Top2α). Also shown to inhibit the in vitro E3 ubiquitin ligase activity of RNF2 and a Bmi1/RNF2 complex, inhibiting H2A/H2AX ubiquitination. Blocks polycomb repressor complex (PRC) 1-mediated histone H2A ubiquitination in vitro and in vivo. | |
| BCC6355 | TC-E 5001 |
| Dual tankyrase (TNKS) inhibitor (Kd values are 79 and 28 nM for TNKS1 and TNKS2 respectively, IC50 = 33 nM for TNKS2) that is devoid of activity at PARP1 and PARP2 (IC50 >19 μM). Inhibits Wnt signaling and stabilizes Axin2 levels. | |
